Search Results - "Harter, P."

Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by Oaknin, A., Bosse, T.J., Creutzberg, C.L., Giornelli, G., Harter, P., Joly, F., Lorusso, D., Marth, C., Makker, V., Mirza, M.R., Ledermann, J.A., Colombo, N.

“…•This ESMO Clinical Practice Guideline provides key recommendations for managing endometrial cancer.•The guideline covers clinical and pathological diagnosis,…”
Get full text

Treatment of recurrent ovarian cancer by Pignata, S, C Cecere, S, Du Bois, A, Harter, P, Heitz, F

“…Despite optimal surgery and appropriate first-line chemotherapy, ∼70%-80% of patients with epithelial ovarian cancer will develop disease relapse. The same…”
Get full text

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy by Hanker, L.C., Loibl, S., Burchardi, N., Pfisterer, J., Meier, W., Pujade-Lauraine, E., Ray-Coquard, I., Sehouli, J., Harter, P., du Bois, A.

“…Despite recent progress in the treatment of ovarian cancer, the majority of patients eventually relapse. There is little information on the effectiveness of…”
Get full text

Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by González-Martín, A., Harter, P., Leary, A., Lorusso, D., Miller, R.E., Pothuri, B., Ray-Coquard, I., Tan, D.S.P., Bellet, E., Oaknin, A., Ledermann, J.A.

“…•This ESMO Clinical Practice Guideline provides key recommendations for managing epithelial ovarian cancer.•The guideline covers clinical and pathological…”
Get full text

Management of borderline ovarian tumors by du Bois, A, Trillsch, F, Mahner, S, Heitz, F, Harter, P

“…Borderline ovarian tumors (BOT) are epithelial tumors of the ovaries with both malignant and non-malignant aspects. On the one hand, they are characterized by…”
Get full text

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial by Ray-Coquard, I., Leary, A., Pignata, S., Cropet, C., González-Martín, A., Marth, C., Nagao, S., Vergote, I., Colombo, N., Mäenpää, J., Selle, F., Sehouli, J., Lorusso, D., Guerra Alia, E.M., Bogner, G., Yoshida, H., Lefeuvre-Plesse, C., Buderath, P., Mosconi, A.M., Lortholary, A., Burges, A., Medioni, J., El-Balat, A., Rodrigues, M., Park-Simon, T.-W., Dubot, C., Denschlag, D., You, B., Pujade-Lauraine, E., Harter, P.

“…In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly…”
Get full text

Neurosurgical resection of multiple brain metastases: outcomes, complications, and survival rates in a retrospective analysis by Niedermeyer, Sebastian, Schmutzer-Sondergeld, M., Weller, J., Katzendobler, S., Kirchleitner, S., Forbrig, R., Harter, P. N., Baumgarten, L. V., Schichor, C., Stoecklein, V., Thon, N.

“…Purpose This study investigates the outcomes of microsurgical resection of multiple brain metastasis (BMs). Methods This retrospective, monocentric analysis…”
Get full text

Study protocol of an exercise and nutrition intervention for ovarian cancer patients during and after first-line chemotherapy (BENITA) - a randomized controlled trial by Maurer, Tabea, Belau, M. H, Zyriax, B-C, Welsch, G, Jagemann, B, Chang-Claude, J, Daubmann, A, Buchholz, A, Glismann, K, Moeller, A, Sehouli, J, Woopen, H, Wimberger, P, Harter, P, Kaiser, S, Maass, N, Kiechle, M, Engler, T, Schmalfeldt, B, Schulz, H

“…Abstract Background In ovarian cancer frequently reported side effects are muscle wasting and malnutrition, leading to frailty, decreased health-related…”
Get full text

Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors by McGee, J., Bookman, M., Harter, P., Marth, C., McNeish, I., Moore, K.N., Poveda, A., Hilpert, F., Hasegawa, K., Bacon, M., Gatsonis, C., Brand, A., Kridelka, F., Berek, J., Ottevanger, N., Levy, T., Silverberg, S., Kim, B.-G., Hirte, H., Okamoto, A., Stuart, G., Ochiai, K.

“…This manuscript reports the consensus statements regarding the design and conduct of clinical trials in patients with newly diagnosed and recurrent epithelial…”
Get full text

When should Surgery be used for Recurrent Ovarian Carcinoma? by Bommert, M., Harter, P., Heitz, F., du Bois, A.

“…Cytoreductive surgery is an important column in the treatment of primary ovarian cancer. Surgical outcome is one of the most important prognostic factors and…”
Get full text

HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer? by Fotopoulou, C., Sehouli, J., Mahner, S., Harter, P., Van Nieuwenhuysen, E., Gonzalez-Martin, A., Vergote, I., Chiva, L., Du Bois, A.

Get full text

Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer by Vergote, I, du Bois, A, Floquet, A, Rau, J, Kim, J.-W, del Campo, J.M, Friedlander, M, Pignata, S, Fujiwara, K, Colombo, N, Mirza, M.R, Monk, B.J, Tsibulak, I, Calvert, P.M, Herzog, T.J, Hanker, L.C, Meunier, J, Lee, J.-Y, Bologna, A, Carrasco-Alfonso, M.J, Harter, P

“…AbstractObjectiveThe AGO-OVAR16 study was designed to test the efficacy, safety, and tolerability of pazopanib maintenance after first-line chemotherapy in…”
Get full text

Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences by Balermpas, P, Rödel, F, Liberz, R, Oppermann, J, Wagenblast, J, Ghanaati, S, Harter, P N, Mittelbronn, M, Weiss, C, Rödel, C, Fokas, E

“…Background: We investigated the prognostic role of tumour-associated macrophages (TAMs) in patients with head and neck squamous cell carcinoma (HNSCC) treated…”
Get full text

Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: Analysis of prospective randomised phase III trials by Mahner, S, Eulenburg, C, Staehle, A, Wegscheider, K, Reuss, A, Pujade-Lauraine, E, Harter, P, Ray-Coquard, I, Pfisterer, J, du Bois, A

“…Abstract Background and Aims Surgery followed by platinum-taxane chemotherapy is the current standard approach to treat advanced ovarian cancer. The impact of…”
Get full text

Surgery and HIPEC in relapse for all patients with ovarian cancer? by Hasson, S P, Ray-Coquard, I, Marth, C, Harter, P

Get full text

Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort by Zang, R Y, Harter, P, Chi, D S, Sehouli, J, Jiang, R, Tropé, C G, Ayhan, A, Cormio, G, Xing, Y, Wollschlaeger, K M, Braicu, E I, Rabbitt, C A, Oksefjell, H, Tian, W J, Fotopoulou, C, Pfisterer, J, du Bois, A, Berek, J S

“…Background: This study aims to identify prognostic factors and to develop a risk model predicting survival in patients undergoing secondary cytoreductive…”
Get full text

Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference by Bookman, M A, Okamoto, A, Stuart, G, Yanaihara, N, Aoki, D, Bacon, M, Fujiwara, K, González-Martín, A, Harter, P, Kim, J W, Ledermann, J, Pujade-Lauraine, E, Quinn, M, Ochiai, K

“…The Gynecologic Cancer InterGroup (GCIG) Fifth Ovarian Cancer Consensus Conference (OCCC) was held in Tokyo, Japan from 7 to 9 November 2015. It provided…”
Get full text

Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer by Harter, P, Gnauert, K, Hils, R, Lehmann, T G, Fisseler-Eckhoff, A, Traut, A, du Bois, A

“…Para-aortic lymphadenectomy is part of staging in early epithelial ovarian cancer (EOC) and could be part of therapy in advanced EOC. However, only a minority…”
Get more information

CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival by Zeiner, P S, Zinke, J, Kowalewski, D J, Bernatz, S, Tichy, J, Ronellenfitsch, M W, Thorsen, F, Berger, A, Forster, M T, Muller, A, Steinbach, J P, Beschorner, R, Wischhusen, J, Kvasnicka, H M, Plate, K H, Stefanović, S, Weide, B, Mittelbronn, M, Harter, P N

“…Despite multidisciplinary local and systemic therapeutic approaches, the prognosis for most patients with brain metastases is still dismal. The role of…”
Get full text

Neoadjuvant chemotherapy in ovarian cancer revisited by Mahner, S, Trillsch, F, Chi, D, Harter, P, Pfisterer, J, Hilpert, F, Burges, A, Weissenbacher, T, du Bois, A

“…Despite the recent publication of two randomized controlled phase III trials addressing neoadjuvant chemotherapy in advanced ovarian cancer, the optimal timing…”
Get full text